Elizabeth Balta
Chief Legal Officer & Corporate SecretaryMs. Elizabeth Balta is Corporate Secretary of Jade Biosciences, Inc. since October 2024 and serves as its Chief Legal Officer since 2026 and served as its General Counsel since October 2024 until 2026. She served as General Counsel of Icosavax, where she led all aspects of the company’s legal affairs from September 2021 until the acquisition of Icosavax by AstraZeneca in February 2024. Prior to joining Icosavax, Ms. Balta served as Associate General Counsel at Seagen Inc. from March 2016 to September 2021 where she helped lead and build the legal affairs group as Seagen transformed into a global, multi-product company. Previously, she oversaw the legal function at Oncothyreon, Inc. where she handled a wide range of corporate, securities, clinical, manufacturing, licensing and transactional matters from 2012 to 2016. Prior to Oncothyreon, Ms. Balta served in roles of increasing responsibility at Emergent BioSolutions Inc. and Trubion Pharmaceuticals, Inc. from 2009 to 2012. Ms. Balta began her legal career as a corporate associate at Fenwick & West LLP and Orrick, Herrington Sutcliffe LLP where she advised early stage and public biopharmaceutical companies. Ms. Balta received her J.D. from Harvard Law School and a B.A. in Human Biology from Stanford University.
Positions
- Company NameJade Biosciences, Inc.Stock CodeJBIOPositionChief Legal Officer & Corporate SecretaryColleagues
- TFTom FrohlichPresident, CEO & Director
- ELEric L. DobmeierIndependent Chairman
- BDBradford D. DahmsCFO and Chief Business Officer
- AJAndrew James KingPresident of Research & Development
- LSLori StewartSenior Vice President of People
- TKTomas KiselakIndependent Director
- LOLawrence Otto KleinIndependent Director
- EMErin M. LavelleIndependent Director
